Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.490 +0.010 (+0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via Globe NewsWire
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
Conference Call Cancelled 
From Agenus Inc.
Via Globe NewsWire
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via Globe NewsWire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET 
From Agenus Inc.
Via Globe NewsWire
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via Globe NewsWire
Agenus to Participate in February Investor Conferences
From Agenus Inc.
Via Globe NewsWire
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Agenus Inc.
Via Globe NewsWire
Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
From Agenus Inc.
Via Globe NewsWire
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
From Agenus Inc.
Via Globe NewsWire
Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma
From Agenus Inc.
Via Globe NewsWire
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
From Agenus Inc.
Via Globe NewsWire
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
From Agenus Inc.
Via Globe NewsWire
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via Globe NewsWire
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
From Agenus Inc.
Via Globe NewsWire
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
From Agenus Inc.
Via Globe NewsWire
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients
From Agenus Inc.
Via Globe NewsWire
Agenus to Host “The Road Taken” R&D Event on November 12, 2022
From Agenus Inc.
Via Globe NewsWire
Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Agenus Inc.
Via Globe NewsWire
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET 
From Agenus Inc.
Via Globe NewsWire
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
Exposures COVID-19
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
From Bristol-Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.